

January 9, 2020

Company Name: Carna Biosciences, Inc.  
 Representative: Kohichiro Yoshino, President and CEO  
 (Stock Code: 4572)  
 Contact: Emi Yamamoto,  
 Director, Business Administration Division  
 (TEL: 81-78-302-7075)

### Revision of Results Forecast for the Fiscal Year Ending December 31, 2019

Carna Biosciences, Inc. (“Carna”) announced today its revised forecast for the fiscal year ending December 31, 2019.

#### 1. Revised consolidated results forecast

The consolidated results forecast for the fiscal year ending December 31, 2019 (January 1, 2019 to December 31, 2019) has been revised as below. The previous forecast was announced on June 25, 2019.

(Millions of yen)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Net profit per share
Previous Forecast (A)	3,038	313	279	214	20.12 yen
<b>Revised Forecast (B)</b>	<b>3,206</b>	<b>968</b>	<b>951</b>	<b>791</b>	<b>72.72 yen</b>
Change from Previous Forecast (B-A)	168	655	672	577	
Change from Previous Forecast (%)	5.5%	209.4%	240.9%	268.9%	
(Ref.) December 31, 2018 Results (Previous Year)	754	(1,144)	(1,159)	(1,210)	(125.02) yen

#### 2. Reason of the revision

Carna has upwardly revised its consolidated sales forecast for the fiscal year ending December 31 (FY2019) by 5.5% to 3,206 million yen from 3,038 million yen primarily due to the strong sales in North America and China at the Drug Discovery Support business. By business segment, sales forecast for the Drug Discovery Support business was revised to 1,078 million yen from 938 million yen as sales of kinase proteins, assay kits, and profiling services were stronger than expected. Sales forecast for the Drug Discovery and Development business was revised to 2,128 million yen from 2,100 million yen due to the difference in the expected foreign exchange rate and the actual rate.

Consolidated operating profit was upwardly revised by 209.4% to 968 million yen from 313 million yen. At the Drug Discovery Support business, operating profit was revised to 403 million yen from 247 million yen due to stronger than expected sales. At the Drug Discovery and Development business, operating profit was revised to 564 million yen from 65 million yen due to the changes in R&D expense. Consolidate R&D expense is expected to be 1,296 million yen from the previous forecast of 1,808 million yen.


As a result, forecast for recurring profit was upwardly revised by 240.9% to 951 million yen and forecast for profit attributable to owners of parent was upwardly revised by 268.9% to 791 million yen.

Fig. 1: Results forecast by business segment

(Millions of yen)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent
<b>Previous Forecast (A)</b>				
Consolidated	3,038	313	279	214
Drug Discovery Support	938	247		
Drug Discovery & Development	2,100	65		
<b>Revised Forecast (B)</b>				
Consolidated	3,206	968	951	791
Drug Discovery Support	1,078	403		
Drug Discovery & Development	2,128	564		
<b>Change (C=B-A)</b>				
Consolidated	168	655	672	577
Drug Discovery Support	140	155		
Drug Discovery & Development	28	499		
<b>Change % (C/A)</b>				
Consolidated	5.5	209.4	240.9	268.9
Drug Discovery Support	14.9	62.9		
Drug Discovery & Development	1.3	766.1		

Fig. 2: Drug discovery support business sales by region



\* The forward-looking statements in this document have been prepared based on information available at the time of the issuance of this release as well as on the certain assumptions considered by the management to be reasonable. Actual results may differ from this forecast due to variety of factors.